Key result
Inpatient SGLT2i initiation linked to ~41% lower risk of CV death or HF hospitalization.
Why the study?
Heart failure is a complex systemic syndrome for which the HLM staging system has been proposed, but its prognostic role according to SGLT2i status and the impact of in-hospital SGLT2i across severity stages required investigation.
Does SGLT2i therapy initiated during hospitalization reduce the composite of cardiovascular death or heart failure hospitalization in patients with heart failure across different HLM severity stages?
Observational (n=711)
Yes
Does SGLT2i therapy initiated during hospitalization reduce the composite of cardiovascular death or heart failure hospitalization in patients with heart failure across different HLM severity stages?
In-hospital initiation of SGLT2i therapy is associated with a significant reduction in cardiovascular death or heart failure hospitalization at 6 months, regardless of heart failure severity as assessed by the HLM staging system.
Answers are grounded in this paper and cite their sources.
May support in-hospital SGLT2i across HF severities; extends data to HLM stages but remains hypothesis-generating pending RCTs.
Heart failure (HF) is a complex systemic syndrome for which the HLM staging system has been proposed to better capture disease complexity. This study investigated the prognostic role of HLM staging according to SGLT2i status and the impact of in-hospital SGLT2i therapy across different stages of HF severity. In this prospective, multicenter, observational study, consecutive patients hospitalized for HF between November 2022 and August 2025 were enrolled and stratified according to HLM stage and according to SGLT2i status at discharge. The primary endpoint was the composite of cardiovascular (CV) death or HF hospitalization at 6-month follow-up. A total of 711 patients were included. The primary endpoint occurred in 82 patients with a significant increase across HLM stages (p < 0.001). Increasing HLM stage was associated with higher risk of adverse outcomes (HR = 1.40; 95% CI 1.02–1.90; p = 0.03), regardless of SGLT2i status. SGLT2i therapy initiation within the index hospitalization was independently associated with a lower risk of the composite endpoint (HR = 0.59; 95% CI 0.38–0.92; p = 0.02) across the HLM severity stages. In this cohort of HF patients, the HLM staging system provided potential clinically meaningful risk stratification irrespective of SGLT2i therapy, and SGLT2i therapy was associated with improved outcomes irrespective of HLM severity. These observations suggest a potential role for integrated pathophysiological staging in risk assessment and therapeutic evaluation.
No takes yet. Share an insight, caveat, or question.
D’Amato et al. (2026) conducted an observational in Heart failure (n=711). SGLT2i therapy vs. No SGLT2i therapy was evaluated on Composite of cardiovascular death or heart failure hospitalization (HR 0.59, 95% CI 0.38-0.92, p=0.02). SGLT2i therapy initiation during hospitalization for heart failure was associated with a lower risk of cardiovascular death or heart failure hospitalization (HR 0.59) across all HLM severity stages.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: